2-169487068-G-C
Variant summary
Our verdict is Pathogenic. Variant got 12 ACMG points: 12P and 0B. PVS1_ModeratePM2PP5_Very_Strong
The NM_152384.3(BBS5):c.143-1G>C variant causes a splice acceptor change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00000755 in 1,456,460 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Consequence
NM_152384.3 splice_acceptor
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 12 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
BBS5 | NM_152384.3 | c.143-1G>C | splice_acceptor_variant | ENST00000295240.8 | NP_689597.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
BBS5 | ENST00000295240.8 | c.143-1G>C | splice_acceptor_variant | 1 | NM_152384.3 | ENSP00000295240 | P1 | |||
BBS5 | ENST00000392663.6 | c.143-1G>C | splice_acceptor_variant | 1 | ENSP00000376431 | |||||
BBS5 | ENST00000443151.1 | c.143-919G>C | intron_variant, NMD_transcript_variant | 5 | ENSP00000406182 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD3 exomes AF: 0.0000398 AC: 10AN: 251204Hom.: 0 AF XY: 0.0000295 AC XY: 4AN XY: 135778
GnomAD4 exome AF: 0.00000755 AC: 11AN: 1456460Hom.: 0 Cov.: 29 AF XY: 0.00000828 AC XY: 6AN XY: 724924
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Bardet-Biedl syndrome 5 Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | DBGen Ocular Genomics | May 19, 2021 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Oct 31, 2018 | - - |
BBS5-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | May 22, 2024 | The BBS5 c.143-1G>C variant is predicted to disrupt the AG splice acceptor site and interfere with normal splicing. This variant has been reported in the homozygous state as well in the heterozygous state with a second pathogenic variant in individuals with inherited retinal disease and Bardet-Biedl syndrome (Torrefranca et al. 2020. PubMed ID: 32811249; Table 3 in Villanueva-Mendoza et al. 2021. PubMed ID: 34828430; Supp. Table 4 in Perea-Romero. 2022. PubMed ID: 35835773; Villafuerte-de la Cruz et al. 2024. Pubmed ID: 38347443). This variant is reported in 0.029% of alleles in individuals of Latino descent in gnomAD. Variants that disrupt the consensus splice acceptor site in BBS5 are expected to be pathogenic. This variant is interpreted as pathogenic. - |
not provided Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Mar 03, 2022 | Canonical splice site variant expected to result in aberrant splicing, although in the absence of functional evidence the actual effect of this sequence change is unknown.; This variant is associated with the following publications: (PMID: 31589614, 34828430) - |
Bardet-Biedl syndrome Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Sep 13, 2023 | This sequence change affects an acceptor splice site in intron 2 of the BBS5 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in BBS5 are known to be pathogenic (PMID: 15137946, 16877420, 26325687, 27708425, 28041643, 29806606). This variant is present in population databases (no rsID available, gnomAD 0.03%). ClinVar contains an entry for this variant (Variation ID: 569727). Disruption of this splice site has been observed in individual(s) with clinical features of Bardet-Biedl syndrome (Invitae). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. It has also been observed to segregate with disease in related individuals. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at